NCR300

Nuwacell Biotechnologies Co., Ltd. · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	NCR300
Sponsor	Nuwacell Biotechnologies Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study on Efficacy and Safety of iNK Cells for CAEBV /EBV-HLH After Allo-HSCT (NA)
A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation (PHASE1)
A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic Syndromes (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NCR300 CI brief — competitive landscape report
NCR300 updates RSS · CI watch RSS
Nuwacell Biotechnologies Co., Ltd. portfolio CI